A year ago many of you were without power in the wake of a sudden and violent storm that has come to be known as the Tom Lee Storm. It is the third most powerful storm, according to Memphis Light Gas and Water Division, in terms of those without power and the damage done. It’s called the Tom Lee storm because the 1950s-era Tom Lee memorial in Tom Lee Park – the obelisk – was toppled and shattered as the obelisk fell from the base. A year later, the base that proclaims Tom Lee “a worthy Negro” remains and the obelisk is in storage.

2. GTx Reports Positive Results in Using Enobosarm to Treat Incontinence - Saturday, May 26, 2018

Memphis-based biopharmaceutical company GTx Inc. has deep roots in Memphis, with AutoZone founder Pitt Hyde being a primary backer of the company since its inception in 1997. In recent years, GTx’s research into the muscle-building compound enobosarm has shifted from patients with breast and lung cancer to women with stress urinary incontinence.

3. GTx Releases More Data From Enobosarm Phase 2 Trial - Wednesday, May 23, 2018

Memphis-based biopharmaceutical company GTx Inc. has released more data supporting the use of its enobosarm drug to treat postmenopausal women with stress urinary incontinence, the most common type of incontinence in women.

4. GTx to Present Trial Results On Phase 2 Enobosarm - Saturday, April 21, 2018

GTx Inc. will present highlights of results from its open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress urinary incontinence (SUI) at the American Urological Association’s annual meeting being in San Francisco, California, May 18-21.

5. GTx to Present Clinical Trial Results on Phase 2 Enobosarm - Thursday, April 19, 2018

GTx Inc. will present highlights of results from its open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress urinary incontinence (SUI) at the American Urological Association’s annual meeting being in San Francisco, California, May 18-21.

6. GTx Completes Enrollment In Latest Clinical Trial - Saturday, April 14, 2018

Memphis-based biopharmaceutical company GTx Inc. reports it has completed patient enrollment several months ahead of schedule in its placebo-controlled, Phase 2 clinical trial of enobosarm in postmenopausal women with stress urinary incontinence, or SUI.

7. GTx Completes Enrollment In Latest Clinical Trial - Thursday, April 12, 2018

Memphis-based biopharmaceutical company GTx Inc. reports it has completed patient enrollment several months ahead of schedule in its placebo-controlled, Phase 2 clinical trial of enobosarm in postmenopausal women with stress urinary incontinence, or SUI.

8. Positive Clinical Trial Results Spike GTx Stock - Saturday, March 10, 2018

Shares of Memphis-based drug maker GTx Inc. closed 38 percent higher Monday on clinical trial results that show its enobosarm drug reduced episodes of urge incontinence by 68 percent in female patients who experienced UI and stress urinary incontinence (SUI).

9. Digest - Tuesday, March 6, 2018

Memphis Grizzlies Suffer 15th Consecutive Loss

The Grizzlies lost their 15th straight game, 119-110 at Chicago, on Wednesday, March 7.

The team has not won since defeating the Phoenix Suns at FedExForum on Jan. 29.

10. Positive Clinical Trial Results On Enobosarm Spike GTx Stock - Monday, March 5, 2018

Shares of Memphis-based drug maker GTx Inc. closed 38 percent higher Monday, March 5, on clinical trial results that show its enobosarm drug reduced episodes of urge incontinence by 68 percent in female patients who experienced UI and stress urinary incontinence (SUI).

11. GTx Announces Positive SUI Trial Results - Saturday, September 16, 2017

Memphis-based biopharmaceutical company GTx Inc. has announced top-line clinical trial results demonstrating that a daily dose of enobosarm 3 mg substantially improved stress urinary incontinence in women, as well as related quality-of-life measurements.

12. GTx Announces Positive SUI Trial Results - Friday, September 15, 2017

Memphis-based biopharmaceutical company GTx Inc. has announced top-line clinical trial results demonstrating that a daily dose of enobosarm 3 mg substantially improved stress urinary incontinence in women, as well as related quality-of-life measurements.

13. GTx Reports $6.4M Loss, Secures $15 Million Loan - Tuesday, August 15, 2017

Memphis-based biopharmaceutical company GTx Inc. saw a net loss of $6.4 million for the second quarter, compared to $6.1 million during the same period in 2016, the company reported Monday, Aug. 14.

14. Last Word: The Old Auto Inspection Station, Beale Field Trip and Re-Democrating - Tuesday, July 25, 2017

Memphis Mayor Willie Herenton has a different version of his 2016 plan to build two youth development centers for juvenile offenders to go to instead of detention at the Wilder Youth Development Center in Somerville. About a year ago, Herenton had tentative plans for two of the New Path centers in Shelby County that would be centers where the offenders could live.

15. GTx to Release New Data from Company’s Work - Tuesday, July 25, 2017

GTx Inc. executive chairman Dr. Robert Wills thinks the Memphis-based biopharmaceutical company is “severely undervalued.”

16. GTx Reports Positive Data From Phase 2 Drug Trial - Saturday, June 17, 2017

GTx Inc. is reporting positive results from the first group of patients in its ongoing Phase 2 clinical trial of enobosarm in postmenopausal women with stress urinary incontinence, or SUI.

17. GTx Reports Positive Data From Phase 2 Drug Trial - Wednesday, June 14, 2017

GTx Inc. is reporting positive results from the first group of patients in its ongoing Phase 2 clinical trial of enobosarm in postmenopausal women with stress urinary incontinence, or SUI.

18. GTx Reports Loss For First Quarter - Saturday, May 20, 2017

Memphis-based biopharmaceutical company GTx Inc. reported a net loss for the quarter ended March 31, as progress continues on the development of its lead product candidate enobosarm, among other highlights.

19. GTx Reports First-Quarter Loss - Tuesday, May 16, 2017

Memphis-based biopharmaceutical company GTx Inc. reported a net loss for the quarter ended March 31, as progress continues on the development of its lead product candidate enobosarm, among other highlights.

20. Evolve Bank & Trust Announces New CFO - Saturday, April 1, 2017

Memphis-based Evolve Bank & Trust has named Mark Mosteller as its new executive vice president and chief financial officer.

21. Evolve Bank & Trust Announces New CFO - Friday, March 31, 2017

Memphis-based Evolve Bank & Trust has named Mark Mosteller as its new executive vice president and chief financial officer.

22. Net Loss Widens For GTx in Fourth Quarter - Friday, March 17, 2017

GTx Inc. reported a fourth-quarter loss of $6.9 million, or 44 cents per share, more than twice the loss of $3.2 million from the same period in 2015.

23. Last Word: Lakeland Date Set, Silos in South Main and Trespassing in Apartments - Thursday, March 16, 2017

Here comes the Governor’s race with Randy Boyd doing the honors here in Memphis Wednesday at the top of the second day of his fly-around. Boyd’s opening sounds very much like he is running as the heir apparent to Gov. Bill Haslam – although there are no heirs in politics, at least not without an election. He talked a lot about hitting workforce development and job goals of the Haslam administration if he is elected Governor in 2018.

24. Net Loss Widens for GTx in Fourth Quarter - Thursday, March 16, 2017

GTx Inc. reported a fourth-quarter loss of $6.9 million, or 44 cents per share, more than twice the loss of $3.2 million from the same period in 2015.

25. GTx Pursues 1-For-10 Reverse Stock Split - Saturday, December 10, 2016

Memphis-based biopharmaceutical company GTx Inc. has announced a reverse stock split of its shares of common stock, at a ratio of 1-for-10.

26. GTx Pursues 1-For-10 Reverse Stock Split - Tuesday, December 6, 2016

Memphis-based biopharmaceutical company GTx Inc. has announced a reverse stock split of its shares of common stock, at a ratio of 1-for-10.

27. GTx Reports $6.9 Million Loss in Third Quarter - Saturday, November 5, 2016

Memphis-based biopharmaceutical company GTx Inc. swung to a loss for the third quarter compared to the year-ago period, the company reported this week.

28. Last Word: An Early Voting Challenge, Raleigh Settlement and Rocky Top Tumult - Friday, November 4, 2016

Early voting in Shelby County ended with some lines Thursday at several of the 21 sites. We should have the final turnout numbers Friday morning and you can get the totals first @tdnpols, www.twitter.com/tdnpols.

29. GTx Reports $6.9 Million Loss in Third Quarter - Friday, November 4, 2016

Memphis-based biopharmaceutical company GTx Inc. swung to a loss for the third quarter compared to the year-ago period, the company reported this week.

30. GTx Reports Advance In Enobosarm Clinical Trial - Saturday, September 17, 2016

Memphis-based GTx Inc. has announced the achievement of the Stage 1 milestone for the 9 mg cohort of its Phase 2 clinical trial of enobosarm to treat breast cancer. It is being tested to treat women with advanced, estrogen receptor positive, androgen receptor positive breast cancer.

31. GTx Reports Advance in Enobosarm Clinical Trial - Monday, September 12, 2016

Memphis-based GTx Inc. announced Thursday the achievement of the Stage 1 milestone for the 9 mg cohort of its Phase 2 clinical trial of enobosarm to treat breast cancer. It is being tested to treat women with advanced, estrogen receptor positive, androgen receptor positive breast cancer.

32. GTx Reports Net Loss In Latest Fiscal Quarter - Saturday, August 13, 2016

Memphis-based biopharmaceutical company GTx Inc. posted a $6.1 million net loss for the quarter ended June 30, compared to a net loss of $48 million for the same period in 2015.

33. Last Word: Wiseacre At The Coliseum, Recession Overdue and Tubby's Schedule - Wednesday, August 10, 2016

So you were at the Mid-South Coliseum every time the doors were open and you could scrape together the price of a ticket south of $10 in the city’s golden age of concerts.

But these days there aren’t that many shows to go to, the ticket prices are much higher and truth be known you probably wouldn’t go to that many shows these days.

34. GTx Reports Net Loss In Latest Fiscal Quarter - Wednesday, August 10, 2016

Memphis-based biopharmaceutical company GTx Inc. posted a $6.1 million net loss for the quarter ended June 30, compared to a net loss of $48 million for the same period in 2015.

35. Snapshot: How Memphis-Based Public Companies are Faring - Saturday, May 28, 2016

Acquisitions have been a common theme among many Memphis-based public companies the past few quarters. Here is a roundup of those transactions and other business highlights from each of the companies.

36. GTx Results Show Narrowing Loss - Saturday, March 5, 2016

Memphis-based biopharmaceutical company GTx Inc. is currently enrolling patients in three clinical trials – two trials evaluating its product enobosarm as a potential treatment for women with advanced breast cancer, and another trial studying enobosarm as a potential treatment for stress urinary incontinence in postmenopausal women.

37. Last Word: Hedgepeth Speaks, Josh Pastner's Future and Big Box Liquor - Friday, March 4, 2016

Where else is there to begin but the Greensward controversy.
And we start with an email from Memphis City Council member Reid Hedgepeth in what is rapidly becoming a Last Word tradition and institution – the email in full.

38. GTx Results Show Narrowing Loss - Friday, March 4, 2016

Memphis-based biopharmaceutical company GTx Inc. is currently enrolling patients in three clinical trials – two trials evaluating its product enobosarm as a potential treatment for women with advanced breast cancer, and another trial studying enobosarm as a potential treatment for stress urinary incontinence in postmenopausal women.

39. The Week Ahead: February 29, 2016 - Monday, February 29, 2016

How was your weekend, Memphis? We know what you’ll be doing Tuesday (voting, of course!), but plenty of nonpolitical happenings grace this week’s calendar too – from a trio of Grizzlies games to a fundraiser supporting fair housing.

40. GTx Back in Black With $34.9M Profit - Saturday, October 31, 2015

Memphis-based biopharmaceutical company GTx Inc.’s lead program has patients enrolling in two Phase 2 clinical trials of its drug enobosarm.

41. GTx Back in Black With $34.9M Profit - Friday, October 30, 2015

Memphis-based biopharmaceutical company GTx Inc.’s lead program has patients enrolling in two Phase 2 clinical trials of its drug enobosarm.

42. FDA Accepts Application for GTx Clinical Trial - Saturday, October 17, 2015

Memphis-based GTx Inc. has announced that the U.S. Food and Drug Administration has accepted the company’s investigational new drug application for a Phase 2 clinical trial to treat postmenopausal women with stress urinary incontinence.

43. FDA Accepts Application For GTx Clinical Trial - Wednesday, October 14, 2015

Memphis-based GTx Inc. has announced that the U.S. Food and Drug Administration has accepted the company’s investigational new drug application for a Phase 2 clinical trial to treat postmenopausal women with stress urinary incontinence.

44. GTx Enrolls First Patient in Enobosarm Clinical Trial - Saturday, October 3, 2015

Memphis-based GTx Inc. has enrolled its first patient in the company’s phase 2 clinical trial of enobosarm, the company’s lead product candidate used to treat women with certain types of breast cancer.

45. GTx Enrolls First Patient in Enobosarm Clinical Trial - Wednesday, September 30, 2015

Memphis-based GTx Inc. has enrolled its first patient in the company’s phase 2 clinical trial of enobosarm, the company’s lead product candidate used to treat women with certain types of breast cancer.

46. GTx Reports Second-Quarter Loss - Friday, August 7, 2015

Memphis-based biopharmaceutical company GTx Inc. reported a net loss of $48 million in the second quarter, wider than its $10.9 million net loss in second quarter 2014.

47. 'En Fuego' - Saturday, August 1, 2015

When Southaven Mayor Darren Musselwhite took office in June 2013, one of the first tasks that landed on his desk was a long-planned regional outlet mall.

The outlet mall, planned for a roughly 33-acre site at Church Road and Interstate 55 in the DeSoto County city, had been on the drawing board for some time, but the recession and its aftermath caused developers and Mississippi officials to put it on hold.

48. GTx Names New Medical Director - Saturday, July 11, 2015

Dr. Diane C. Young is the new vice president, chief medical officer, of GTx Inc.

The Memphis-based biopharmaceutical company announced Young’s appointment Wednesday, July 8.

49. GTx Names New Medical Director - Thursday, July 9, 2015

Dr. Diane C. Young is the new vice president, chief medical officer, of GTx Inc.

The Memphis-based biopharmaceutical company announced Young’s appointment Wednesday, July 8.

50. GTx Stock Performance Pleases Analysts - Saturday, July 4, 2015

Memphis-based biopharmaceutical company GTx is making investors and analysts happier these days.

A recent Zacks Equity Research note said it was "pretty encouraging" that estimates for GTx's stock have moved higher in recent weeks, with the analyst sentiment rising in tandem with a 37 percent stock price gain over the past month. Shares were up 2 cents to $1.49 during afternoon trading Wednesday, July 1.

51. GTx Stock Performance Pleases Analysts - Thursday, July 2, 2015

Memphis-based biopharmaceutical company GTx is making investors and analysts happier these days.

A recent Zacks Equity Research note said it was "pretty encouraging" that estimates for GTx's stock have moved higher in recent weeks, with the analyst sentiment rising in tandem with a 37 percent stock price gain over the past month. Shares were up 2 cents to $1.49 during afternoon trading Wednesday, July 1.

52. Mark Mosteller Joins Evolve Bank & Trust - Wednesday, July 1, 2015

Mark E. Mosteller Sr. recently joined Evolve Bank & Trust as executive vice president, accounting and finance.
The new role includes a variety of responsibilities, including management of the accounting and finance department team, accounting internal controls, internal and external financial reporting, budgeting and forecasting, taxes and treasury management. Mosteller also works with senior and executive management and the board on accounting, finance and operational issues.

53. Evolve Bank & Trust Adds Executive Vice President - Saturday, June 6, 2015

Evolve Bank & Trust has added Mark Mosteller as its new executive vice president of accounting and finance.

54. Evolve Bank & Trust Adds Executive Vice President - Wednesday, June 3, 2015

Evolve Bank & Trust has added Mark Mosteller as its new executive vice president of accounting and finance.

55. Snapshot: Memphis-Based Public Companies - Saturday, May 30, 2015

Here's a look at what's going on at the dozen public companies headquartered in Memphis:

AutoZone Inc.

AutoZone Inc. is one of the largest auto parts retailers and distributors in the U.S., with a store count of 5,476 as of Feb. 14. Since 1998, the company has repurchased $15.7 billion worth of its own shares. At the end of March, AutoZone continued its share buyback program with the authorization to buy back another $750 million in company stock. The company followed that news with plans to pursue a $650 million debt offering to be used for “general corporate purposes.” – Andy Meek

56. GTx Narrows Loss in First Quarter - Saturday, May 16, 2015

GTx Inc. reported a net loss for the first quarter of $2.4 million, compared to a $9 million loss during the same period in 2014.

57. GTx Narrows Loss in First Quarter - Tuesday, May 12, 2015

GTx Inc. reported a net loss for the first quarter of $2.4 million, compared to a $9 million loss during the same period in 2014.

58. GTx Partners With UT Research Foundation - Saturday, April 25, 2015

GTx Inc. has announced it’s entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation to develop the company’s proprietary selective androgen receptor degrader technology.

59. GTx Partners With UT Research Foundation - Friday, April 24, 2015

GTx Inc. has announced it’s entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation to develop the company’s proprietary selective androgen receptor degrader technology.

60. GTx Shifts Stock Listing, Granted Grace Period - Saturday, April 11, 2015

Memphis-based GTx Inc. has announced that it’s shifted its stock market listening from The NASDAQ Global Market to The NASDAQ Capital Market, a transfer that was effective on March 19.

61. GTx Shifts Stock Listing, Granted Grace Period - Monday, April 6, 2015

Memphis-based GTx Inc. has announced that it’s shifted its stock market listening from The NASDAQ Global Market to The NASDAQ Capital Market, a transfer that was effective on March 19.

62. GTx Reports Full-Year, Fourth-Quarter Loss - Thursday, March 5, 2015

Memphis-based biopharmaceutical company GTx Inc. has reported a net loss of $14.5 million for the quarter ended Dec. 31 and an annual net loss of $39.4 million for 2014.

63. Johnson & Johnson Exec Named GTx Chairman - Saturday, February 21, 2015

Memphis-based GTx has a new chairman – Dr. Robert Wills, who’s joining effective March 2 after retiring from Johnson & Johnson.

64. GTx Taps Johnson & Johnson Executive as New Chairman - Thursday, February 19, 2015

GTx has a new chairman: Dr. Robert Wills, who’s joining effective March 2 after retiring from Johnson & Johnson.

65. Greenfield Voted to Lead Veterinary Dental College - Wednesday, December 17, 2014

Dr. Barden Greenfield has been unanimously voted president-elect for the American Veterinary Dental College. In 2009, Greenfield started Your Pet Dentist, the umbrella that incorporates his involvement in Memphis Veterinary Specialists, Nashville Specialists and the Animal Emergency and Specialty Clinic of Little Rock. He has been on the AVDC board for three years, serving as chair of the PR Committee and as a member of the Credentials Committee.

66. Change on Tap for Many Local Public Companies - Saturday, May 31, 2014

Here’s a snapshot of recent news and developments at some of the publicly traded companies based in Memphis, reflecting the influence these companies have and the shadows they cast both in Memphis and beyond, in industries that range from bioscience to banking.

67. Docs Settle Insider GTx Trading Claims for $100,000 - Monday, May 26, 2014

SAN BERNARDINO, Calif. (AP) – Two Southern California doctors will pay more than $100,000 to settle insider-trading allegations involving a drug they were testing.

The Securities and Exchange Commission announced Monday that Dr. Franklin Chu and Dr. Daniel Lama, both of San Bernardino, agreed to pay the fines. They didn't acknowledge any wrongdoing.

68. GTx Scientific Officer Resigns - Saturday, April 19, 2014

James Dalton, the chief scientific officer and vice president of Memphis-based GTx Inc., will resign effective Aug. 31 to become dean of the University of Michigan College of Pharmacy.

69. GTx Scientific Officer Resigns - Thursday, April 17, 2014

James Dalton, the chief scientific officer and vice president of Memphis-based GTx Inc., will resign effective Aug. 31 to become dean of the University of Michigan College of Pharmacy.

70. Events - Thursday, April 17, 2014

Memphis Pink Palace Museum will host Dr. Jim Dalton of GTx Corp., presenting “Genetics, Race and Medicine,” Thursday, April 17, from 5 p.m. to 7 p.m. at the museum, 3050 Central Ave. Cost is free. Visit memphismuseums.org.

71. Events - Wednesday, April 16, 2014

Kiwanis Club of Memphis will meet Wednesday, April 16, from noon to 1 p.m. at The University Club of Memphis, 1346 Central Ave. Don Johnson, bishop of the Episcopal Diocese of West Tennessee, will speak. Cost is $18 for nonmembers.

72. Steiner Resigns as CEO of GTx - Friday, April 4, 2014

Dr. Mitchell Steiner has resigned effective Thursday from being CEO and vice chairman of GTx, the Memphis-based company he co-founded.

73. GTx Reports Net Loss, Improved Cash Position - Saturday, March 8, 2014

Memphis-based GTx reported a net loss of $7.8 million for the quarter ended Dec. 31 and an annual net loss of $42.1 million for 2013.

That compares to net losses of $10.7 million for the last quarter of 2012 and a net loss of $27.1 million for all of 2012.

74. GTx Reports Net Loss, Improved Cash Position - Thursday, March 6, 2014

Memphis-based GTx reported a net loss of $7.8 million for the quarter ended Dec. 31 and an annual net loss of $42.1 million for 2013.

That compares to net losses of $10.7 million for the last quarter of 2012 and a net loss of $27.1 million for all of 2012.

75. RedRover Adds Trio of Employees - Saturday, December 21, 2013

RedRover Sales & Marketing has added three new employees to the roster.

They are creative director Carl Cottam, corporate trainer Lori Guy and marketing account executive Jennifer Seidman.

76. RedRover Adds Trio of Employees - Monday, December 16, 2013

RedRover Sales & Marketing has added three new employees to the roster.

They are creative director Carl Cottam, corporate trainer Lori Guy and marketing account executive Jennifer Seidman.

77. Performance Ranges Widely at Local Companies - Saturday, October 26, 2013

Here’s a snapshot of the recent performance of some of Memphis’ publicly traded companies – businesses that cast a shadow far beyond the Memphis city limits in industries including finance, package delivery and bioscience.

78. GTx Layoffs Show Drug Market’s Volatility - Thursday, October 3, 2013

The layoffs at Memphis-based GTx Inc., announced Tuesday, Oct. 1, came with the resignation of the drug manufacturing company’s chief financial officer and pay cuts for GTx’s top three leaders.

79. GTx to Lay Off 60 Percent of Staff - Wednesday, October 2, 2013

Memphis-based GTx is laying off 60 percent of its employees, according to a filing with the U.S. Securities and Exchange Commission.

The company expects to complete the downsizing, which will impact 53 “non-executive employees,” by Oct. 31, according to an 8K filing with the SEC. That will leave about 35 people.

80. GTx Treatment Fails to Meet Goals - Tuesday, August 20, 2013

Shares of GTx Inc. plunged on Monday after the drugmaker said an experimental treatment with the potential to prevent and treat muscle wasting in cancer patients failed to meet its goals in two late-stage clinical trials.

81. GTx Says Muscle Drug Misses Late-Stage Study Goals - Monday, August 19, 2013

Shares of GTx Inc. plunged Monday after the drug developer said its potential treatment for muscle wasting in lung cancer patients fell short of some main goals in late-stage clinical testing.

82. West Appointed Director of Wings Cancer Foundation - Wednesday, July 10, 2013

Chris West has been appointed executive director of The Wings Cancer Foundation, a nonprofit organization that provides care to cancer patients and their families. He has been interim director for the past six months.

83. GTx Posts Quarterly, Yearly Net Loss - Friday, February 22, 2013

Memphis-based biopharmaceutical company GTx Inc. has reported net loss of $10.7 million for the fourth quarter ended Dec. 31 compared to a similar $10.7 million net loss in Q4 2011.

84. GTx Drug Receives Fast-Track Status From FDA - Saturday, January 12, 2013

An experimental GTx Inc. treatment for muscle wasting in patients with a form of lung cancer will be reviewed under the Food and Drug Administration’s fast-track program.

85. GTx Drug Receives Fast-Track Status From FDA - Wednesday, January 9, 2013

An experimental GTx Inc. treatment for muscle wasting in patients with a form of lung cancer will be reviewed under the Food and Drug Administration’s fast-track program.

86. GTx Drug Receives Fast-Track Status From FDA - Tuesday, January 8, 2013

MEMPHIS (AP) – An experimental GTx Inc. treatment for muscle wasting in patients with a form of lung cancer will be reviewed under the Food and Drug Administration's fast-track program. Its shares climbed more than 12 percent in premarket trading.

87. GTx Rebounds in Third Quarter - Friday, November 9, 2012

Memphis-based biopharmaceutical company GTx Inc. on Thursday, Nov. 8, reported net income of $7.4 million for the third quarter, fueled primarily from $18.8 million in net proceeds from the sale in early October of Fareston, a breast treatment medication.

88. Entrepreneurial Ecosystem - Monday, October 1, 2012

Maybe you’re a startup founder who wants to rub shoulders with your peers, pitch investors in the hope of landing venture capital and talk to a lawyer about drawing up paperwork.

Maybe you’re a veteran researcher who’s got a side project that looks like it could turn into something big. Or maybe you’ve got little more than an idea on the back of a napkin.

89. GTx Narrows Q2 Loss - Thursday, August 9, 2012

GTx Inc. Wednesday, Aug. 8, reported a net loss of $10.4 million for the second quarter, compared to a net loss of $10.7 million for the same period in 2011.

90. GTx Narrows Q2 Loss - Wednesday, August 8, 2012

GTx Inc. Wednesday, Aug. 8, reported a net loss of $10.4 million for the second quarter, compared to a net loss of $10.7 million for the same period in 2011.

91. UTHSC Breaks Ground On Research Building - Monday, June 11, 2012

The University of Tennessee Health Science Center broke ground Friday, June 8, on its $49 million Translational Science Research Building, which will be built on the grassy lot at the northwest corner of Union Avenue and South Manassas Street.

92. Hill Joins Barge, Waggoner, Sumner & Cannon as CFO - Wednesday, May 23, 2012

Certified Public Accountant Jason Hill has joined engineering and architectural firm Barge, Waggoner, Sumner & Cannon Inc. as chief financial officer.

93. UTHSC Prof. Receives $325K For Drug Discovery Instrument - Wednesday, May 9, 2012

Dr. Wei Li, associate professor in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (UTHSC), is the principal investigator of a $325,000 grant from the Office of the Director, a subsidiary of the National Institutes of Health.

94. GTx Reports $11.1 Million Q1 Net Income Loss - Wednesday, May 9, 2012

Memphis-based biopharmaceutical company GTx Inc. on Tuesday, May 8, reported an $11.1 million net loss for the first quarter, compared to a net loss of $2.6 million for the same period in 2011.

95. Steiner, GTx Inc. Prepare For Next Step of Journey - Monday, April 16, 2012

Dr. Mitchell Steiner recently returned from a trip to Eastern Europe, where he visited hospitals participating in international clinical trials for the drug enobosarm, which is being developed by his Memphis-based public biopharmaceutical company GTx Inc.

96. Many Questions Raised Before Going Public - Monday, April 16, 2012

As Facebook prepares for its multibillion-dollar initial public offering (IPO) next month, it sheds light on how companies – including local ones – decide whether to go public or not.

Memphis-based pharmaceutical company GTx Inc. went public in 2004 and local paper producer Verso Paper Corp. held its IPO in 2008, but the overall number of publicly traded companies both locally and nationally has dropped over the past two decades.

97. Performance Of Memphis Public Cos. Varies Widely - Monday, April 16, 2012

Memphis is home to several publicly traded companies that have made an indelible mark on industries ranging from transportation to finance and manufacturing.

Here’s a snapshot of how those companies are faring at the moment. (For a detailed look at AutoZone, see related story, "The Fast Lane.")

98. GTx Sends FDA Info on Prostate Drug - Thursday, April 5, 2012

GTx Inc. said Wednesday, April 4, that it is starting discussions with the U.S. Food and Drug Administration about resuming trials of its experimental prostate cancer drug Capesaris.

99. Ambitious Growth on Tap For Med Communications - Monday, March 5, 2012

Pharmaceutical consulting firm Med Communications Inc. is expanding its presence in Memphis, with plans to soon move into a larger office space to accommodate anticipated growth over the next several years.

100. Panel: State Has ‘Robust’ Bioscience Community - Monday, February 27, 2012

Members of the region’s scientific, medical, academic and business communities seeking more knowledge about innovative early-stage investment strategies in the biosciences packed the ballroom of The University Club, 1346 Central Avenue, on Thursday, Feb. 23, for a panel discussion hosted by Memphis Bioworks Business Association.